US 12,391,689 B2
Synthesis of key intermediate of KRAS G12C inhibitor compound
Andrew Thomas Parsons, Cambridge, MA (US); Brian McNeil Cochran, San Diego, CA (US); William Powazinik, IV, Thousand Oaks, CA (US); and Marc Anthony Caporini, Belmont, MA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by Amgen Inc., Thousand Oaks, CA (US)
Filed on Mar. 8, 2022, as Appl. No. 17/689,741.
Application 17/689,741 is a continuation of application No. 16/685,841, filed on Nov. 15, 2019, granted, now 11,299,491.
Claims priority of provisional application 62/768,802, filed on Nov. 16, 2018.
Prior Publication US 2022/0220112 A1, Jul. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/235 (2006.01); A61K 31/341 (2006.01); A61K 31/4985 (2006.01); C07C 69/76 (2006.01); C07C 309/24 (2006.01); C07D 307/06 (2006.01)
CPC C07D 471/04 (2013.01) [C07C 69/76 (2013.01); C07C 309/24 (2013.01)] 13 Claims
 
1. A composition, the composition comprising a compound of Formula 4:

OG Complex Work Unit Chemistry
and a compound of Formula B:

OG Complex Work Unit Chemistry